Ospemifene for Genitourinary Syndrome of Menopause: Choosing the Oral Option Because the Local One Isn't Available to Her
The two therapies guidelines prefer both require an act her body won't tolerate, leaving an oral option whose warning label was written for an entire drug class, not for her.
Two treatments have already failed Harriet L., 70, and neither failed for any reason the drugs themselves could answer for. Her genitourinary syndrome of menopause has been severe and progressive for the past four years — vaginal dryness, burning, and dyspareunia that ended her intimate relationship with her partner of twelve years, by her own account, and urinary urgency she has learned to plan her days around. She has no diabetes, no history of venous thromboembolism personally or in her immediate family, and no other chronic conditions.
Two separate attempts at vaginal estrogen cream, tried over the past year, both ended within days: a pelvic floor physical therapy evaluation confirmed genuine pelvic floor hypertonicity with involuntary guarding severe enough that any vaginal insertion — cream applicator, ring, or suppository — produces pain she rates as unbearable, not merely uncomfortable. That finding rules out both guideline-preferred first-line options for GSM, vaginal estrogen and vaginal prasterone, not on efficacy or systemic-risk grounds but on a physical tolerance ground neither drug's own safety profile can address. Ospemifene, an oral selective estrogen receptor modulator, is approved in the US and specifically indicated in Europe for exactly her situation — women who are not candidates for local vaginal estrogen therapy. It also carries labeling tied to the broader SERM class's documented venous thromboembolism signal, a caution serious enough that European regulators required a dedicated five-year post-authorization safety study of the drug specifically before settling the question. That study has since reported: in Nordstrom's cohort the thromboembolism rate on ospemifene ran at 3.7 per 1,000 person-years against 11.5 on other SERMs and 11.3 in women with untreated atrophy — which means the drug-specific number, and not the class-level warning, is the one that describes a woman with her risk profile.
A class-wide warning label against a drug-specific safety study
I'd start ospemifene. Vaginal estrogen and vaginal prasterone are both preferred first for GSM precisely because they minimize systemic exposure, but that preference assumes the patient can actually use them — and her pelvic floor evaluation confirms she genuinely cannot. Ospemifene is specifically indicated in Europe for women who aren't candidates for local vaginal estrogen therapy. That's not a loose analogy to her situation, it's a description of it.
I'm not opposed, but I want the caution stated plainly before we move forward. Ospemifene's labeling exists because SERMs as a class carry a well-documented venous thromboembolism signal — serious enough that the European Medicines Agency mandated a five-year postauthorization safety study of this specific drug before finalizing its labeling. That wasn't a reflexive warning; it was a regulator treating a real class-level signal as worth confirming directly, and I'd want us to say which study answered it rather than gesture at reassurance.
That study has actually reported, and I think its results matter more here than the original caution that prompted it. Nordstrom and colleagues ran the post-authorization cohort in the MarketScan claims database — 8,188 ospemifene users against 11,777 users of other SERMs and 220,242 women with untreated vulvovaginal atrophy — and put venous thromboembolism at 3.7 per 1,000 person-years on ospemifene, against 11.5 for the other SERMs and 11.3 for the untreated women. Lower than the class it belongs to, and lower than leaving the condition alone.
And she has no personal or family thromboembolism history, no smoking, no immobility — none of the risk factors that would put her outside the population that real-world data describes.
Agreed: start ospemifene 60mg daily, with explicit counseling that benefit is often delayed up to several months and that she should report any leg swelling, pain, or shortness of breath immediately given the drug's labeled precaution, even though her individual risk profile is reassuring.
No substantive disagreement among the three voices by the end — the clinical pharmacologist's caution was raised and directly addressed by the real-world safety data rather than left standing unresolved, a genuine case of the debate converging rather than one voice simply overruling another.